- Home
- TVRD vs NCZ Comparison
TVRD vs NCZ Comparison
Compare TVRD & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- NCZ
- Stock Information
- Founded
- TVRD 2017
- NCZ 2003
- Country
- TVRD United States
- NCZ United States
- Employees
- TVRD N/A
- NCZ N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- TVRD Health Care
- NCZ Finance
- Exchange
- TVRD Nasdaq
- NCZ Nasdaq
- Market Cap
- TVRD 246.5M
- NCZ 228.3M
- IPO Year
- TVRD N/A
- NCZ N/A
- Fundamental
- Price
- TVRD $29.92
- NCZ $13.53
- Analyst Decision
- TVRD Strong Buy
- NCZ
- Analyst Count
- TVRD 5
- NCZ 0
- Target Price
- TVRD $59.20
- NCZ N/A
- AVG Volume (30 Days)
- TVRD 23.2K
- NCZ 533.0K
- Earning Date
- TVRD 08-14-2025
- NCZ 01-01-0001
- Dividend Yield
- TVRD N/A
- NCZ 12.16%
- EPS Growth
- TVRD N/A
- NCZ N/A
- EPS
- TVRD N/A
- NCZ N/A
- Revenue
- TVRD N/A
- NCZ N/A
- Revenue This Year
- TVRD N/A
- NCZ N/A
- Revenue Next Year
- TVRD N/A
- NCZ N/A
- P/E Ratio
- TVRD N/A
- NCZ N/A
- Revenue Growth
- TVRD N/A
- NCZ N/A
- 52 Week Low
- TVRD $8.13
- NCZ $2.50
- 52 Week High
- TVRD $34.31
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- TVRD 65.43
- NCZ 68.84
- Support Level
- TVRD $22.91
- NCZ $13.07
- Resistance Level
- TVRD $31.54
- NCZ $13.43
- Average True Range (ATR)
- TVRD 1.65
- NCZ 0.11
- MACD
- TVRD 0.61
- NCZ 0.01
- Stochastic Oscillator
- TVRD 81.28
- NCZ 94.19
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.